<DOC>
	<DOC>NCT01926483</DOC>
	<brief_summary>The investigators hypothesized that the Neoadjuvant Chemoradiotherapy was a beneficial treatment for Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer, so we try to evaluate the security of treatment, the QoL of patients and the influence to the PFS and OS.</brief_summary>
	<brief_title>Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection</brief_title>
	<detailed_description>Scheme: Patients will receive different chemotherapy regimens depending on the pathological type. Squamous cell carcinoma:Docetaxel/Cisplatin and concurrent radiation (46Gy/23f) followed by surgery, consolidate Docetaxel/Cisplatin 2 cycles. Non-squamous cell carcinoma:Pemetrexed/Cisplatin and concurrent radiation (46Gy/23f) followed by surgery, consolidate Pemetrexed/Cisplatin 2 cycles.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>18≤Age≤65; ECOG performance status of 0 or 1; Pathological diagnosis with Stage IIIAN2 NSCLC which is clinically resectable and the N2 is diagnosed by either mediastinoscopy,EBUS,PET/CT; WBC≥4.0×109/l, ANC≥1.5×109/l, PLT≥100.0×109/l, Hb≥90g/l;hepatorenal function is normal; Without a history of other malignancies before enrollment, except for nonmelanoma skin cancer, in situ cervical cancer; The patient can understand the research and sign the informed consent. Female in pregnancy or lactating;Female of childbearing age without contraception; With acute infection or other serious underlying disease; With a significant history of neurological of psychiatric disease，including the dementia which may affect the ability to understand and sign the informed consent; Have received other treatment within the last 30 days before enrollment; With uncontrollable diabetes(blood glucose is unstable after treatment or FBG≥8mol/L).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Stage IIIA-N2 NSCLC</keyword>
</DOC>